PAVmed Inc
PAVM0.527USD
+0.001+0.23%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
8.83MCap. mercado
0.12P/E TTM
Más Datos de PAVmed Inc Compañía
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates through three lines of business: Medical Devices, Diagnostics, and Digital Health. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is focused on enhanced personalized cancer care through remote patient monitoring using implantable vascular access port with wireless communication combined with an oncologist-designed remote digital healthcare platform.
Información de la empresa
Símbolo de cotizaciónPAVM
Nombre de la empresaPAVmed Inc
Fecha de salida a bolsaJul 27, 2016
Director ejecutivoDr. Lishan Aklog, M.D.
Número de empleados39
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 27
Dirección360 Madison Avenue
CiudadNEW YORK
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal10017
Teléfono12129494319
Sitio Webhttps://pavmed.com/
Símbolo de cotizaciónPAVM
Fecha de salida a bolsaJul 27, 2016
Director ejecutivoDr. Lishan Aklog, M.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Michael J. Glennon
Mr. Michael J. Glennon
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
81.67K
--
Dr. Lishan Aklog, M.D.
Dr. Lishan Aklog, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
78.72K
--
Mr. Ronald M. (Ron) Sparks
Mr. Ronald M. (Ron) Sparks
Independent Director
Independent Director
65.00K
--
Mr. Dennis M. Mcgrath
Mr. Dennis M. Mcgrath
President, Chief Financial Officer
President, Chief Financial Officer
50.83K
--
Mr. Sundeep Agrawal, M.D.
Mr. Sundeep Agrawal, M.D.
Director
Director
12.20K
--
Mr. Michael A. Gordon
Mr. Michael A. Gordon
General Counsel, Secretary
General Counsel, Secretary
--
--
Ms. Debra J. White
Ms. Debra J. White
Independent Director
Independent Director
--
--
Mr. Timothy (Tim) Baxter
Mr. Timothy (Tim) Baxter
Independent Director
Independent Director
--
--
Mr. Matt Riley
Mr. Matt Riley
Director of Investor Relations
Director of Investor Relations
--
--
Mr. Shaun M. O'Neil
Mr. Shaun M. O'Neil
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Michael J. Glennon
Mr. Michael J. Glennon
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
81.67K
--
Dr. Lishan Aklog, M.D.
Dr. Lishan Aklog, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
78.72K
--
Mr. Ronald M. (Ron) Sparks
Mr. Ronald M. (Ron) Sparks
Independent Director
Independent Director
65.00K
--
Mr. Dennis M. Mcgrath
Mr. Dennis M. Mcgrath
President, Chief Financial Officer
President, Chief Financial Officer
50.83K
--
Mr. Sundeep Agrawal, M.D.
Mr. Sundeep Agrawal, M.D.
Director
Director
12.20K
--
Mr. Michael A. Gordon
Mr. Michael A. Gordon
General Counsel, Secretary
General Counsel, Secretary
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 16 de may
Actualizado: vie., 16 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Tasso Partners, LLC
14.61%
First Manhattan Co. LLC
4.05%
Dubreville (Anthony Michael)
3.44%
Pavilion Venture Partners, L.L.C.
1.69%
Geode Capital Management, L.L.C.
0.53%
Other
75.68%
Accionistas
Accionistas
Proporción
Tasso Partners, LLC
14.61%
First Manhattan Co. LLC
4.05%
Dubreville (Anthony Michael)
3.44%
Pavilion Venture Partners, L.L.C.
1.69%
Geode Capital Management, L.L.C.
0.53%
Other
75.68%
Tipos de accionistas
Accionistas
Proporción
Corporation
16.31%
Individual Investor
5.92%
Investment Advisor
5.88%
Investment Advisor/Hedge Fund
0.72%
Hedge Fund
0.19%
Research Firm
0.14%
Venture Capital
0.13%
Other
70.72%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
101
5.16M
29.28%
+2.77M
2025Q1
106
5.16M
31.74%
+3.03M
2024Q4
110
2.41M
17.67%
+156.53K
2024Q3
120
2.58M
24.42%
+197.13K
2024Q2
133
1.94M
20.61%
-301.78K
2024Q1
169
2.19M
26.52%
+433.78K
2023Q4
185
1.60M
20.86%
-48.73K
2023Q3
208
1.30M
18.00%
-268.87K
2023Q2
221
1.26M
18.65%
-731.24K
2023Q1
227
1.31M
20.36%
-649.18K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Tasso Partners, LLC
2.57M
14.61%
+2.57M
--
Feb 21, 2025
First Manhattan Co. LLC
714.10K
4.05%
+14.10K
+2.01%
Mar 31, 2025
Dubreville (Anthony Michael)
606.26K
3.44%
+606.26K
--
Aug 30, 2024
Pavilion Venture Partners, L.L.C.
297.11K
1.69%
--
--
Apr 22, 2025
Geode Capital Management, L.L.C.
92.67K
0.53%
+13.20K
+16.62%
Mar 31, 2025
Glennon (Michael J)
81.67K
0.46%
+1.00
+0.00%
Apr 22, 2025
The Vanguard Group, Inc.
81.49K
0.46%
--
--
Mar 31, 2025
Aklog (Lishan)
78.72K
0.45%
--
--
Apr 22, 2025
BlackRock Institutional Trust Company, N.A.
72.66K
0.41%
--
--
Mar 31, 2025
CAPTRUST Financial Advisors
65.05K
0.37%
+65.05K
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Dec 04, 2023
Merger
15<1
Dec 04, 2023
Merger
15<1
Dec 04, 2023
Merger
15<1
Dec 04, 2023
Merger
15<1
Fecha
Tipo
Relación
Dec 04, 2023
Merger
15<1
Dec 04, 2023
Merger
15<1
Dec 04, 2023
Merger
15<1
Dec 04, 2023
Merger
15<1
